logo
Share SHARE
FONT-SIZE Plus   Neg

Sucampo, Abbott Say Sucampo Pharma, Ltd. Gets Approval For AMITIZA In Japan

Sucampo Pharmaceuticals, Inc. (SCMP) and Abbott (ABT) announced that Sucampo Pharma, Ltd., a wholly owned subsidiary of Sucampo Pharmaceuticals, has received approval from the Ministry of Health, Labor and Welfare in Japan for AMITIZA (lubiprostone), a prescription medicine for the treatment of chronic constipation.

Sucampo submitted a marketing application to the Japanese Pharmaceuticals and Medical Devices Agency for approval to market AMITIZA in September 2010. The application included data from a Phase 3 efficacy trial in 124 Japanese patients as well as from a long-term open-label safety trial in 209 Japanese patients who received lubiprostone for up to 48 weeks. The application also included data from previous trials conducted in the United States, Canada and Europe.

"We are very pleased to receive Japan's first-ever approval for a prescription medicine for chronic constipation as it helps us achieve our objective of bringing medicines with novel mechanisms of action to patients with unmet medical needs on a global basis," said Ryuji Ueno, Sucampo's Chairman and Chief Executive Officer. "We look forward to working with Abbott to meet the needs of these patients in Japan."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Sanofi SA were gaining around 2 percent in the early morning trading in Paris after the French drug giant reported significantly higher profit in its first quarter, benefited by 4.4 billion euros gains from the disposal of its Merial animal healthcare unit and higher sales. For fiscal 2017, Sanofi said it continues to expect Business earnings per share to be stable to negative 3 percent. Shares of UBS Group AG were gaining around 4 percent in the early morning trading after the Swiss banking giant reported Friday significantly higher profit in its first quarter, despite weakness in net interest income. The company also proposed a dividend. Looking ahead, UBS said it is well positioned to mitigate various market challenges... Alphabet Inc. (GOOG, GOOGL), the parent company of Google, Thursday reported an increase in profit for the first quarter, driven largely revenue growth in search and advertising. Alphabet's first-quarter profit rose to $5.43 billion or $7.73 per share from $4.21 billion or $6.02 per share last year. On...
comments powered by Disqus
Follow RTT